Policy & Regulation

The Inflation Reduction Act (IRA) changes the way Medicare pays for prescription drugs. These changes will impact various stakeholders, including Medicare, Medicare enrollees, drug manufacturers, and others.

The generic injectable drug market has recently experienced numerous shortages, which impose substantial public health costs. One potential cause of these shortages is low profitability of generic injectables. This brief examines the profitability of recently launched generic injectables.

March-in authority allows the federal government to grant licenses on privately owned patents for inventions developed with federal funding provided certain statutory requirements are met. It was designed to ensure that the benefits of the American taxpayers’ investment in research and development are reasonably accessible to the public.

During the pandemic period, telehealth utilization increased among both urban and rural enrollees in Medicaid, with urban enrollees sustaining greater gains in telehealth utilization at the end of 2021. This Issue Brief is part of a series of ASPE Issue Briefs examining changes in Medicaid utilization of services delivered via telehealth by enrollee and provider characteristics.

The Centers for Medicare & Medicaid Services (CMS) Innovation Center is in the process of developing the Medicare $2 Drug List (M2DL) Model. This would allow Part D plan sponsors to offer a standardized list of generic drugs for a copayment of $2 or less for a month’s supply that would not be subject to prior authorization, quantity limits, or other utilization management restrictions.

This study examined the extent therapist practices and nursing homes adopted telehealth services for physical therapy (PT), occupational therapy (OT), and speech-language pathology (SLP); explored the major challenges and facilitators in adopting telerehabilitation services, and whether these services were effective in addressing patient care and staffing needs during the public health emergenc

Health Information Technology (HIT) was identified as a critical component of the HHS Roadmap for Behavioral Health Integration. To support the implementation of the Roadmap, an ASPE study was conducted to provide an overview of HIT adoption and utilization among behavioral health providers.

Since March 2020, HHS and DEA have allowed health care practitioners to initiate controlled medications via a telehealth visit without first conducting an in-person medical evaluation, representing a substantial change in how these medications, and the conditions they are used to treat, can be managed.

Prescription drug prices are a top concern for policymakers and the public, but little data is available on prescription drug prices or other costs that contribute to premiums for commercial drug coverage.

IntroductionMeans-tested benefits are designed to support basic needs such as food, health insurance, and child care for households with low incomes. When considering whether to take a new job opportunity that will increase their income, recipients of these benefits may be forced to consider trade-offs. For example: